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Case Presentation
In 2014, a 69-year-old Panamanian female with a past medical 
history of diabetes mellitus type 2 and the presence of a 
pterygium on her conjunctiva had had resection a month prior 
of her pterygium and placement of an amniotic membrane graft 
to her left eye for which she had been treated with longterm 
corticosteroids.  She presented to the emergency department of 
a hospital in Panama City, Panama with a history of one week of 
evolution of swelling of the right side of her face, ipsilateral eye 
proptosis and odynophagia.  A large ulcer (3 X 4 cm) in her hard 
palate was evident. 
Her labs showed anemia (hematocrit 27%), leukocytosis (15,000 
cells/mL3), neutrophilia (73%), acute kidney injury (creatinine 
2.0 mg/dL) and diabetic ketoacidosis with an elevated anion gap 
of 16 meq/L.  As part of the emergency diagnostic approach, she 
had a nasal endoscopy during which they observed a necrotic 
lesion in the septum with cotton-like texture at the level of the 
nostrils. (Video 1) 
The CT scan revealed inflammatory changes, a fluid collection 
and inflammatory necrotic tissue in the masticatory space that 
extended on the right to the pterygopalatine fossa and orbital 
apex (Figure 1).  There was involvement (anterior to posterior) 
of her right eye (proptosis), compromise of intra- and extra-
conal fat, the medial rectus muscle, and the superior orbital 
fissure, as well as asymmetry of the right cavernous sinus.
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Video 1 Nasal endoscopic view of each nostril and a hard palate 
ulcer with necrotic tissue in a patient with Mucormycosis.
Figure 1 CT head scan with inflammatory necrotic tissue in the 
masticatory space that extended to the pterygopalatine fossa and the 
orbital apex.  Post-surgical inflammatory changes are visible (large 
single arrow) as well as invasion of infection into the right carotid artery 
(line with two arrowheads).
Abstract
Mucorales fungal infection is a fungal disease with potentially fatal outcomes.  The most frequent 
involvement in humans comes from the orders known as Mucorales and Entomophthorales. 
Mucorales is more acute and has a predilection for immunocompromised patients.  Mucorales are 
associated with an affinity for vessels, which leads to invasion and infarction of tissue.  Mucormycosis 
is a devastating complication that can be a life threatening fungal invasion in many patients in an 
immunocompromised state.
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She was taken to the operating room three times for debridement 
and cleaning of necrotic tissue.  The orbit decompression was 
draining pus.  An open approach was performed including a 
subtotal maxilectomy (palate/pterygoid lamina).  It was closed 
with a gingival flap of the oral palate. A tissue sample was taken 
to the pathology department where it showed tubular structures 
compatible with a fungus.  Gomori stains and periodic acid-
Schiff stain findings were consistent with mucormycosis 
(Figure 2).
Treatment included initially caspofungin alone without 
improvement, then amphotericin B deoxycholate was added as 
salvage therapy.  Amphotericin B was given at a dose of 50mg 
daily (1 mg/kg/day) until a total cumulative dose of 2580 mg 
was given.  Complications related to the medication were seen, 
especially nephrotoxicity due to the amphotericin B, therefore it 
was reduced to 30 mg/day (0.6 mg/kg/day). 
After five months of dual antifungal therapy and multiple 
debridements, risk factors related to comorbidities continued 
to play an important role for lack of control of the disease. 
Poor glycemic control at home, nephrotoxicity and electrolyte 
disturbances complicated the outcome.  She returned with a 
probable cerebral vascular event secondary to extension of the 
mucormycosis to the brain and died a week later. 
Discussion
Rhinocerebral mucormycosis is a devastating infection with 
high mortality of 35% for patients with no underlying condition 
[1].  Its relationship with immunosuppression makes treatment 
of this fungal infection difficult.  The most frequent involvement 
in humans comes from the orders known as Mucorales and 
Entomophthorales [2].  Infections usually begin in the paranasal 
sinuses following inhalation of sporangiospores and may 
involve the orbit, palate, face, nose or brain [2].  The important 
characteristic for the diagnosis of this disease is the vascular 
invasion and tissue necrosis similar to what we observed in 
the pathology of our patient, with wide hyphae (10-20µm), and 
right-angled branching without septa. 
Entomophthorales in the tropics are associated with chronic 
conditions of the skin and subcutaneous tissue [2].  Mucorales 
has an affinity for vessels and leads to invasion and infarction 
of tissue [3].  Mucor species are typically avirulent due to a lack 
of thermo-tolerability in the presence of a healthy host immune 
system, but will manifest with disease in the presence of 
immunosuppression[4].  Rhizopus orizae is the most common 
isolated filamentous fungus from patients with mucormycosis 
causing at least 90% of cases related to rhinocerebral 
mucormycosis [1].  Mucormycosis appears as an opportunistic 
disease due to certain risk factors (Table 1).  The number of 
patients with predisposing risk factors has increased making the 
disease more prevalent.  The overall mortality rate for a diabetic 
patient is as high as 44% [2].  Our patient’s main comorbidity 
was the decompensation of her diabetes, which accounted for 
her predisposition to, and the persistence of, her infection.   
Prevention of mucormycosis can be attained with control 
of diabetes mellitus by maintaining normal glycemia levels, 
correcting ketoacidosis, and avoiding corticosteroid therapy. 
Proper treatment with a favorable outcome depends on both 
medical treatment and good initial debridement.
Mucormycosis invasiveness may be based on the availability of 
iron in serum and tissue [5].  Iron will promote neurotropism 
and invasion.  The low pH in uncontrolled diabetes also 
decreases the activity of transferrin, which results in more 
free iron in the blood for Mucorales [6].  The rhinocerebral, 
pulmonary and disseminated presentation of mucormycosis 
all have necrosis, thrombosis and invasion of blood vessels in 
common [5].  1,3-β-D-glucan detection is not useful in this kind 
of infection due to extremely low content of this molecule in 
Mucorales [5,7]. 
It is well known that macrophages and neutrophils have an 
important role in immune defense. The functional defects 
caused by therapeutic interventions such as corticosteroids 
play a crucial risk factor for Mucorales to infect [5]. Diabetes 
alone can impair the function of neutrophils contributing to 
the severity of mucormycosis in patients with ketoacidosis 
[8]. Macrophages have a dimished phagocytotic effect 
and neutrophils have a diminished chemotactic and 
oxidative burst due to the low pH during ketoacidosis [6]. 
2
Figure 2 
(A) Periodic acid Schiff stain (PAS) of necrotic nasal tissue showing a vessel with fungal invasion
(B) Enhancement of necrotic nasal tissue structures showing mucormycosis with silver staining (Gomori)
JRGH Vol 2, (1) 2019
Table 1 Risk factors for acquiring mucormycosis.
A   B






Uncontrolled Diabetes/Diabetic ketoacidosis 
Chronic metabolic acidosis 
Treatment with deferoxamine 
 
One study found that the host receptor, glucose regulated 
protein (GPR78), facilitates the invasion of human endothelial 
cells by R. oryzae due to the presence of high iron and glucose 
concentrations [9]. In the diabetic murine model, there was a 
direct relationship between an increased expression of this 
protein and the damage of endothelial cells [9].
This is a disease condition without many therapeutic options due 
to the severity of disease. The standard treatment recommended 
in rhinocerebral mucormycosis is amphotericin B with 
debridement, but the combined treatment of amphotericin 
B plus either an echinocandin or an azole with debridement 
was shown to improve survival in three cases [10,11]. Drugs 
that have an FDA approved indication for mucormycosis are 
amphotericin B with its lipid derivatives, and isavuconazonium 
sulfate, the pro-drug of isavuconazole, which was not available 
until 2015 (a year after this patient’s death).
The genome sequence of R. oryzae has led to the discovery of 
genes involved in ergosterol biosynthesis and two genes that 
code for 1,3-β-D-glucan synthase [12]. These findings help us 
understand why there is evidence that caspofungin inhibits 
glucan synthase activity of R. oryzae. 1,3-β-D-glucan is a small 
part of the Mucorales cell wall and echinocandins are the 
only antifungal to target the cell wall – most target the cell 
memebrane.  Thus, echinocandins, may be considered during 
failure as an additional component of salvage therapy [12].
This patient was offered a combination of amphotericin B 
deoxycholate plus caspofungin based on studies of rescue 
therapy [13] as a last measure. However, she ultimately died due 
the mold infection.  From the time of her diagnosis, she lived 
approximately six months.
Rhinocerebral mucormycosis is invasive and carries a poor 
prognosis. Diabetes mellitus is a major risk factor and its 
incidence is increasing globally, so patients presenting with 
uncontrolled diabetes should be investigated for possible 
mucormycosis.  There is not a specific treatment duration. 
It depends on clinical evaluation of the affected area and the 
presence of the healing process after multiple debridements. 
Amphotericin B or isavuconazonium sulfate is good initial 
treatment if it is combined with surgical removal of necrotic 
tissue. Combined therapy with an echinocandin may be an 
efficacious and less toxic alternative for maintenance therapy. 
Infections with Mucorales are present worldwide.  It has been 
well documented in Europe, India, Japan and the United States 
[3,6,14,15]. More recent documentation of cases has come 
from Burkina Faso, Iran and Taiwan [16-18]. There has been 
a documented predilection for mucormycosis from August to 
October/November.  One study was from Japan, which has its 
typhoon season at that time, but Iran and Israel, with more arid 
climates, also found a higher incidence during that time period 
[17,19,20]. As communities in the US become increasingly 
international, diabetes becomes more prevalent and solid organ 
transplants are performed more frequently, it is important 
to recognize the need to expand the differential diagnoses to 
include mucormoycosis, accordingly. 
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